Vivus Gets Good News From Diabetes Drug Test

Vivus’ Phase II study for Qnexa, used for treating cardiovascular complications that arise from Type 2 diabetes, produced positive results.

The study was a randomized, multicenter, double-blind, placebo-controlled prospective trial with subjects receiving the drug or placebo. A subset analysis of subjects with high cardiovascular risk factors showed significant improvement with the drug, according to the company.

Results included reductions in blood pressure, a 32 percent decrease of triglyceride levels and a 35 percent reduction in fasting plasma glucose from patients’ baseline levels.